Arrowstreet Capital
RARE icon

Arrowstreet Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Arrowstreet Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,000
Closed -$554K – 2476
2020
Q4 		$554K Buy
+4,000
New +$475K ﹤0.01% 1990

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital's RARE Position: Q1 2021 in Review

Arrowstreet Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 4,000 shares — an estimated $554K sold.

Arrowstreet Capital first reported a position in RARE in Q4 2020 and held it in 1 quarter. The position peaked at $554K in Q4 2020. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

  • Arrowstreet Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 4,000 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $554K.
  • Arrowstreet Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Ultragenyx Pharmaceutical position peaked at $554K in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.